Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $106.75

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $110.5455.

GPCR has been the topic of a number of analyst reports. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Citizens Jmp cut their price target on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective for the company. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Finally, Wolfe Research assumed coverage on Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company.

Structure Therapeutics Trading Up 5.6%

Shares of NASDAQ:GPCR opened at $48.16 on Thursday. Structure Therapeutics has a 12-month low of $15.80 and a 12-month high of $94.90. The business’s fifty day simple moving average is $42.22 and its 200-day simple moving average is $57.96. The company has a market capitalization of $3.42 billion, a PE ratio of -55.36 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Research analysts predict that Structure Therapeutics will post -1.64 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new stake in shares of Structure Therapeutics in the 1st quarter worth $434,000. Avidity Partners Management LP acquired a new stake in shares of Structure Therapeutics in the 1st quarter worth $1,446,000. Bank of America Corp DE boosted its position in shares of Structure Therapeutics by 617.0% in the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after purchasing an additional 195,454 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Structure Therapeutics by 5.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after purchasing an additional 264,833 shares in the last quarter. Finally, Eversept Partners LP boosted its position in shares of Structure Therapeutics by 8.2% in the 1st quarter. Eversept Partners LP now owns 138,036 shares of the company’s stock worth $6,653,000 after purchasing an additional 10,475 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.